Adagene To Test Its Anti-CTLA-4 Monoclonal Antibodies In Combination With Keytruda In Solid Tumors
- Adagene Inc (NASDAQ: ADAG) has entered into a clinical trial collaboration and supply agreement with Merck & Co Inc (NYSE: MRK).
- The agreement includes two clinical studies to evaluate Adagene's anti-CTLA-4 monoclonal antibody (mAb) candidates, ADG116 and ADG126, in combination with Merck's Keytruda (pembrolizumab), for patients with advanced/metastatic solid tumors.
- "ADG116 program is at the 3 mg/kg dose level now, which is where the commercial CTLA-4 therapy had been approved previously in mono and combination for specific indications," said Steven Fischkoff, interim Chief Medical Officer of Adagene.
- Price Action: ADAG shares are up 3.97% at $20.67 during the premarket session on the last check Thursday.
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Posted-In: Briefs Solid TumorBiotech News Health Care Contracts Small Cap General
